Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | IMC-F106C + unspecified PD-1 antibody |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IMC-F106C | IMC F106C|IMC F106C | IMC-F106C is T-cell receptor, in fusion with anti-CD3 single-chain variable fragment, that targets cancer cells expressing PRAME (NCI Thesaurus). | ||
unspecified PD-1 antibody | Experimental PD-1 antibody | Immune Checkpoint Inhibitor 141 PD-L1/PD-1 antibody 83 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04262466 | Phase Ib/II | IMC-F106C IMC-F106C + unspecified PD-1 antibody IMC-F106C + unspecified PD-L1 antibody | Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | Recruiting | USA | 1 |